X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs GLENMARK PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB GLENMARK PHARMA DR. REDDYS LAB/
GLENMARK PHARMA
 
P/E (TTM) x 34.3 14.3 240.2% View Chart
P/BV x 3.4 3.8 89.1% View Chart
Dividend Yield % 0.8 0.3 251.1%  

Financials

 DR. REDDYS LAB   GLENMARK PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
GLENMARK PHARMA
Mar-17
DR. REDDYS LAB/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs3,397993 342.1%   
Low Rs2,560729 351.0%   
Sales per share (Unadj.) Rs856.5325.5 263.1%  
Earnings per share (Unadj.) Rs78.039.3 198.4%  
Cash flow per share (Unadj.) Rs139.948.7 287.5%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %0.70.2 289.1%  
Book value per share (Unadj.) Rs739.8159.2 464.7%  
Shares outstanding (eoy) m165.74282.17 58.7%   
Bonus/Rights/Conversions BBESOP-  
Price / Sales ratio x3.52.6 131.4%   
Avg P/E ratio x38.221.9 174.3%  
P/CF ratio (eoy) x21.317.7 120.3%  
Price / Book Value ratio x4.05.4 74.4%  
Dividend payout %25.75.1 504.0%   
Avg Mkt Cap Rs m493,632242,991 203.1%   
No. of employees `00022.713.0 174.9%   
Total wages/salary Rs m31,06816,408 189.3%   
Avg. sales/employee Rs Th6,259.07,083.9 88.4%   
Avg. wages/employee Rs Th1,369.81,265.4 108.3%   
Avg. net profit/employee Rs Th569.7855.1 66.6%   
INCOME DATA
Net Sales Rs m141,96191,857 154.5%  
Other income Rs m1,715374 459.0%   
Total revenues Rs m143,67692,230 155.8%   
Gross profit Rs m24,72220,367 121.4%  
Depreciation Rs m10,2662,644 388.3%   
Interest Rs m6342,373 26.7%   
Profit before tax Rs m15,53715,724 98.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m3490-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m2,9653,827 77.5%   
Profit after tax Rs m12,92111,088 116.5%  
Gross profit margin %17.422.2 78.5%  
Effective tax rate %19.124.3 78.4%   
Net profit margin %9.112.1 75.4%  
BALANCE SHEET DATA
Current assets Rs m96,83768,746 140.9%   
Current liabilities Rs m84,19927,027 311.5%   
Net working cap to sales %8.945.4 19.6%  
Current ratio x1.22.5 45.2%  
Inventory Days Days7385 86.3%  
Debtors Days Days9896 102.2%  
Net fixed assets Rs m102,55224,132 425.0%   
Share capital Rs m829282 293.8%   
"Free" reserves Rs m121,79244,643 272.8%   
Net worth Rs m122,62144,925 272.9%   
Long term debt Rs m5,44945,363 12.0%   
Total assets Rs m218,165117,639 185.5%  
Interest coverage x25.57.6 334.5%   
Debt to equity ratio x01.0 4.4%  
Sales to assets ratio x0.70.8 83.3%   
Return on assets %6.211.4 54.3%  
Return on equity %10.524.7 42.7%  
Return on capital %12.919.1 67.4%  
Exports to sales %54.60-   
Imports to sales %9.40-   
Exports (fob) Rs m77,520NA-   
Imports (cif) Rs m13,274NA-   
Fx inflow Rs m81,67056,152 145.4%   
Fx outflow Rs m26,3558,084 326.0%   
Net fx Rs m55,31548,068 115.1%   
CASH FLOW
From Operations Rs m21,4446,574 326.2%  
From Investments Rs m-18,404-7,124 258.4%  
From Financial Activity Rs m-3,6925,432 -68.0%  
Net Cashflow Rs m-1,1441,992 -57.4%  

Share Holding

Indian Promoters % 25.5 48.3 52.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 6.9 78.3%  
FIIs % 35.3 34.4 102.6%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.5 145.7%  
Shareholders   75,885 56,727 133.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   J.B.CHEMICALS  ALEMBIC LTD  CIPLA  ELDER PHARMA  SUVEN LIFE  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views on News

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jan 19, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - TTK HEALTHCARE COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS